⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL324327 | 0.74 | — | — | |
| SCHEMBL1464459 | 0.71 | — | — | |
| SCHEMBL2068735 | 0.70 | — | — | |
| SCHEMBL2068162 | 0.70 | — | — | |
| SCHEMBL1515232 | 0.70 | — | — | |
| SCHEMBL481763 | 0.70 | — | — | |
| SCHEMBL2078173 | 0.70 | — | — | |
| SCHEMBL1465377 | 0.70 | — | — | |
| SCHEMBL2885675 | 0.67 | NQO1 (0.34) | — | |
| SCHEMBL17529629 | 0.67 | MCHR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123967-A1 | SARM1 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SENYA PHARMACEUTICALS, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| EP-3867238-B1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | claimed |
| CN-114341124-A | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2022-04-12 | — | — | CN | claimed |
| US-20210380582-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2021-12-09 | — | — | US | claimed |
| WO-2020081848-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-04-23 | — | — | WO | claimed |
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| US-8828908-B2 | Herbicidally active bicyclic 1,3-dione compounds | SYNGENTA LIMITED (GB) | 2014-09-09 | — | — | US | claimed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | claimed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | claimed |
| EP-2470508-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | claimed |
| WO-2011025541-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | claimed |
| WO-2024123967-A1 | SARM1 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SENYA PHARMACEUTICALS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | disclosed |
| US-11771695-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-6274556-B1 | ADMINISTERING POLYPEPTIDE DERIVATIVE TO TREAT INFLAMMATORY BOWEL DISEASE AND TO PREVENT LEUKOCYTE INFILTRATION INTO TISSUES | MILLENNIUM PHARMACEUTICALS, INC. | 2001-08-14 | — | — | US | disclosed |
| EP-0871670-A2 | INHIBITORS OF MAdCAM-1-MEDIATED INTERACTIONS AND METHODS OF USE THEREFOR | Leukosite, Inc. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997025351-A2 | INHIBITORS OF MAdCAM-1-MEDIATED INTERACTIONS AND METHODS OF USE THEREFOR | LEUKOSITE, INC. (US) | 1997-07-17 | — | — | WO | disclosed |